The Global Chromoblastomycosis Treatment Market is expected to grow at a CAGR of approximately 6.3% during the forecast period, 2017-2023.
Chromoblastomycosis Treatment Market Scenario:
Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there is about a million type of fungal species, yet nearly 300 are capable of causing infections or disease in humans. Most of these cases are seen in people with compromised immune systems and can occur almost in any part of the body.
A type of fungal infection known as systemic mycosis is affecting the internal organs of the body. During this, fungal infection can spread and affect other organs of the body. The rising cases of immunological diseases is a reason for increased probability of systemic mycosis. Thus, the developing novel treatment for chromoblastomycosis with fewer side effects is the primary objective of manufacturing companies.
The newly launched azoles such as voriconazole and itraconazole, are the gold standard drugs for antifungal therapy. Chromoblastomycosis infections need to be treated with antifungal medication such as itraconazole, terbinafine, posaconazole, amphotericin B. Often, the treatment for chromoblastomycosis requires surgery to scrape off the infected tissue. The growth of the market is primarily driven by increasing incidents of fungal infections, rising prevalence of immunological diseases, availability of wide range of products, and increasing awareness about the fungal infections. However, the existence of misbranded drugs and their side effects may slow the growth of the market. The treatment of fungal infections is available in multiple dosage forms such as oral and intravenous medicines. Furthermore, the medications are also available in the form of sprays, creams, solutions, and shampoos.
Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/5685
Chromoblastomycosis Treatment Market Key Players
Some of key the players in the global chromoblastomycosis treatment market are Astellas Pharma (Japan), Biocon Limited (India), Abbott Laboratories (U.S.), Merck Sharp and Dohme (U.S.), Gilead Sciences (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), F. Hoffman La Roche (Switerzland), Cadila Pharmaceuticals Limited (India), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switerzland), and others.
The global chromoblastomycosis treatment market consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas region accounted for the largest market share for the global chromoblastomycosis treatment market owing to the high prevalence of this infection in the South American region along with the existence of the huge patient population. Chromoblastomycosis is referred as a ubiquitous, and subcutaneous type of fungal infection. According to a survey, it was found that Brazil displayed a high incidence rate, i.e., 1.6 cases per 10,000 population for chromoblastomycosis.
The European region accounted for the second largest market which is followed by Asia Pacific. Moreover, the Asia Pacific region is anticipated to witness fast growth over the forecast period for the global chromoblastomycosis treatment market. The prevalence of subcutaneous mycoses was found to be 8 cases per 100,000 persons. Moreover, the annual incidence of mycoses increased from 6.9% to 7.4% from 2010 to 2013.
The Middle East region is expected to grow at a steady pace owing to the factors such as the growing emphasis on research and development in the healthcare sector, and extensive development of healthcare infrastructure. The Madagascar Island in Africa is considered to exhibit the highest incidence of chromoblastomycosis in the world.
The global chromoblastomycosis treatment market is segmented on the basis of species, types, diagnosis, treatment, and end-users.
By the species, the global chromoblastomycosis treatment market is segmented into Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola, and others.
On the basis of the disease type, the global chromoblastomycosis treatment market is segmented into nodular type, tumoral type, verrucous type, plaque type, and others.
On the basis of the diagnosis, the global chromoblastomycosis treatment market is segmented into blood test, immunodiagnosis, histopathology and mycological examination, tissue biopsy, and others. The immunodiagnosis is classified into enzyme-linked immunosorbent assay (ELISA), and immunodiffusion, and others.
On the basis of the treatment, the global chromoblastomycosis treatment market is segmented into surgery, antifungal drugs, amphotericin B therapy, thermotherapy, laser therapy, photodynamic therapy, adjuvant therapy, and others. The surgery is classified into cryosurgery, curettage, electrodesiccation, surgical excisions, and others. Furthermore, the antifungal drugs are categorized into oral itraconazole, oral terbinafine, posaconazole, isavuconazole, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
Access Report Details @ https://www.marketresearchfuture.com/reports/chromoblastomycosis-treatment-market-5685
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar